On Monday, Keefe, Bruyette & Woods affirmed its positive stance on Willis Towers Watson (NASDAQ:WTW), maintaining both its Outperform rating and the $359.00 price target for the company's shares. The endorsement comes as the firm anticipates the company's December 3 Investor Day to provide insights into its operations following the TRANZACT acquisition.
The analyst from Keefe, Bruyette & Woods expressed expectations for the Investor Day to include a comprehensive review of Willis Towers Watson's post-TRANZACT business portfolio. Particular attention is likely to be paid to the Health, Wealth & Career segment, which is believed to be undervalued.
The firm also anticipates that Willis Towers Watson will continue to experience mid-single-digit or higher organic growth, as well as above-average annual increases in margins and free cash flow. However, specific earnings per share (EPS) guidance is not expected to be provided during the event.
Further, the company's capital management strategies are set to be a topic of discussion at the Investor Day. Keefe, Bruyette & Woods suggests that these strategies will likely include a commitment to growing dividends annually, maintaining steady stock buybacks—underscored by the recent $1 billion increase in share repurchase authorization—and a consistent approach to mergers and acquisitions.
The $359.00 price target set by Keefe, Bruyette & Woods is based on a 20.0 times multiple of the firm's estimated 2025 earnings per share for Willis Towers Watson. This valuation reflects a confident outlook on the company's financial performance and strategic initiatives in the coming years.
Willis Towers Watson's Investor Day, scheduled for December 3, is expected to be a pivotal event for current and potential investors, providing a clearer picture of the company's future trajectory and financial health.
In other recent news, Willis Towers Watson reported a robust third-quarter performance in 2024, with a 6% rise in organic revenue growth, largely driven by a 10% increase in Risk & Broking and a 4% rise in Health, Wealth & Career segments.
The company's adjusted operating margin improved by 190 basis points to 18.1%, and adjusted diluted earnings per share reached $2.93, marking a 31% increase year-over-year. Furthermore, the Board of Directors authorized an additional $1 billion to its share repurchase program, underlining the firm's commitment to returning value to shareholders.
Truist Securities reaffirmed its Buy rating on Willis Towers Watson shares, anticipating clear guidance from the company following the successful completion of its Transformation program. This milestone is expected to streamline operations, enhance efficiency, and contribute to a healthy financial performance. Keefe, Bruyette & Woods (KBW) also raised its price target for Willis Towers Watson from $352 to $359, maintaining its Outperform rating on the stock.
In addition to these financial highlights, Willis Towers Watson announced strategic partnerships and divestitures, including the sale of TRANZACT and an investment in Atomos. Despite a 1% decline in Benefits, Delivery & Outsourcing due to strong prior-year comparables and client insourcing effects, the company remains optimistic about achieving its 2024 targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.